Craig Gracey, who serves as the Chief Accounting Officer at Omada Health, Inc. (NASDAQ:OMDA), recently completed a transaction involving the exercise and immediate sale of company equity. According to an amended Form 4 filing submitted to the Securities and Exchange Commission, Gracey sold 2,083 shares of Omada Health common stock on June 24, 2026. The aggregate proceeds from this sale amounted to approximately $39,601.
Transaction Details and Trading Plan
The shares were divested at a weighted average price of $19.0118, with individual execution prices ranging between $19.00 and $19.03 per share. This sale was facilitated under a pre-arranged 10b5-1 trading plan that Gracey established on March 13, 2026. The filing serves as an amendment to an original Form 4 initially submitted on June 26, 2026. The amendment was necessary to include the option exercise transaction, which was inadvertently omitted from the initial report, and to adjust the reported amount of securities beneficially owned following the sale.
Prior to the sale, Gracey exercised options to acquire the 2,083 shares at a strike price of $6.57 per share, a transaction valued at $13,685. These options are classified as derivative securities, specifically stock options granting the right to purchase shares, with an expiration date of October 23, 2034. The vesting schedule for these options commenced on September 9, 2024, with 25% vesting on the first anniversary and 1/48th of the total shares vesting monthly thereafter.
Post-Transaction Holdings and Market Context
Following the transaction, Gracey directly holds 15,441 shares of Omada Health common stock and maintains 39,584 unexercised stock options. The sale occurred against a backdrop of recent market appreciation for OMDA. Since the transaction date, Omada Health’s stock has climbed to $22.98, reflecting a strong 49% gain over the past six months. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value. Investors can access detailed valuation metrics and comprehensive Pro Research Reports covering OMDA and 1,400+ other US equities on the platform.
Corporate Performance and Governance Updates
In other recent developments, Omada Health Inc. reported its financial results for the first quarter of 2026, showcasing a positive earnings surprise. The company achieved an EPS of -$0.05, which exceeded the forecasted -$0.08. Revenue for the quarter reached $78 million, indicating a 42% increase compared to the same period last year. Additionally, Citizens raised its price target for Omada Health to $21 from $18, maintaining a Market Outperform rating. This adjustment reflects the company’s growth outlook, as noted by analyst Constantine Davides.
In corporate governance news, Omada Health held its 2026 Annual Meeting of Stockholders, where Sean Duffy and Trevor Fetter were elected as Class I Directors. Both directors received a significant number of votes in favor and will serve until the 2029 annual meeting. These developments highlight the company’s recent progress and strategic direction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Is now the time to buy OMDA? ProPicks AI evaluates OMDA every month against thousands of alternatives using 100+ financial metrics. It found Siemens Energy (+231.5%) and Sandisk (+189%) before the crowd did. Could OMDA be next—or is there a better opportunity in the same space? Don't wait to find out. July Sale - 60% Off InvestingPro